Opinion on Oncology in Europe

Published within

« | ... | 14 | 15 | 16 | 17 | 18 | 19 | 20 | 21 | 22 | » »|

Type Product title / description Pub Price
Expert View
Expert View

ESMO 2009: novel 'super-selective' agent shows early signs of efficacy in metastatic melanoma

Phase I data for the orally available novel BRAF inhibitor PLX4032 presented at the European Society for Medical Oncology Congress 2009 are causing cautious excitement in the melanoma market. This step towards personalized cancer care has the potential to revolutionize treatment of this tumor type, but only if early efficacy signals are carried through to the end of late-phase clinical studies.

Published By Datamonitor
30 Sep 2009
Expert View
Expert View

FIGO 2009: focus moves towards cervical cancer and overactive bladder

Among the key developments at this year's International Federation of Gynecology and Obstetrics meeting, pharmaceutical companies aimed to improve awareness of overactive bladder. Elsewhere, the reduction of mortality due to cervical cancer emerged as a key theme among delegates, with discussions of vaccine strategies not only in the developed world but also in developing countries.

Published By Datamonitor
13 Oct 2009
Expert View
Expert View

EASD 2009: Lantus defended amid allegations of increased cancer risk

Datamonitor attended this year's European Association for the Study of Diabetes meeting in Vienna, Austria. Following the issuance of guidance on a potential link between Lantus and increased cancer rates in June 2009, presenters at the conference discussed the current evidence and its limitations. However, a potential mechanism by which insulin could promote cancer cell growth was also proposed.

Published By Datamonitor
14 Oct 2009
CommentWire
CommentWire

Antigenics: Oncophage EU marketing application likely to fail

Antigenics is seeking EU approval for Oncophage in early-stage renal cell carcinoma. Despite there currently being no approved drugs for the post-surgical treatment of adjuvant kidney cancer in the EU or US, Oncophage's application is expected to fail. Antigenics will have to provide more robust evidence of Oncophage's efficacy if it wishes to gain approval in the lucrative US and EU markets.

Published By Datamonitor
22 Oct 2009
CommentWire
CommentWire

Amgen: Vectibix disappoints in colorectal cancer but hope remains

Amgen's Vectibix has failed to meet a secondary endpoint of overall survival in patients with KRAS wild-type metastatic colorectal cancer. This is a setback as initial positive results for the drug had suggested a strong positioning against Erbitux in the first-line. However, Vectibix did show a trend towards an improvement in survival, and Amgen may now consider further trials on this basis.

Published By Datamonitor
06 Nov 2009
Expert View
Expert View

Genentech/Roche: UK's NICE remains negative over Avastin for colorectal cancer

NICE, the UK's cost effectiveness watchdog, has again rejected the use of Avastin in combination with chemotherapy for first-line colorectal cancer patients, arguing that the drug isn't a cost effective use of NHS resources. Limited access to Avastin in the NHS will allow Erbitux to further penetrate the first-line colorectal cancer market in the UK, for which it was approved earlier this year.

Published By Datamonitor
25 Nov 2009
Expert View
Expert View

ASH 2009: Novartis looks to position Tasigna as an alternative to Gleevec in CML

At this year's American Society of Hematology meeting, researchers presented results from a Phase III study comparing Tasigna and Gleevec in newly diagnosed chronic myeloid leukemia. While Tasigna's efficacy is impressive, it is unlikely that the drug will achieve the same market penetration as Gleevec in newly diagnosed patients due to fierce competition from Sprycel.

Published By Datamonitor
11 Dec 2009
Expert View
Expert View

ASH 2009: competition between Velcade and Revlimid intensifies in multiple myeloma

Datamonitor attended this year's American Society of Hematology annual meeting in New Orleans, focusing on key developments in hematological malignancies. While recent trial results are likely to support new applications for Velcade and Revlimid in first-line multiple myeloma, the data also suggest that the future of treatment may actually be a combination of the two.

Published By Datamonitor
11 Dec 2009
CommentWire
CommentWire

Roche: novel Herceptin formulation promises greater convenience

Having stepped up lifecycle management for its leading breast cancer monoclonal antibody, Herceptin, Roche hopes to encourage uptake of a more convenient formulation of the drug. This strategy could help to conserve its share of an increasingly competitive market, but may be challenging to implement due to concerns over compliance and financial incentives to prescribe intravenous cancer drugs.

Published By Datamonitor
22 Jan 2010
Expert View
Expert View

Avastin suffers setback in gastric cancer but potential remains

A Phase III trial evaluating Avastin in combination with standard first-line chemotherapy in previously untreated patients with advanced gastric cancer has failed to meet its primary endpoint. While this is undoubtedly a setback in terms of sales expansion opportunities for Roche, it is unlikely to have a negative impact on physician perception and Avastin's overall potential in the cancer market.

Published By Datamonitor
23 Feb 2010

« | ... | 14 | 15 | 16 | 17 | 18 | 19 | 20 | 21 | 22 | » »|

No help is available.